INT277882

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.71
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 13
Disease Relevance 1.60
Pain Relevance 0.26

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lysosome (Ids)
Anatomy Link Frequency
brain 2
plasma 1
blood 1
myoblasts 1
Ids (Mus musculus)
Pain Link Frequency Relevance Heat
Central nervous system 399 94.44 High High
Thalamus 81 49.36 Quite Low
intrathecal 8 44.76 Quite Low
Spinal cord 8 41.80 Quite Low
Antihistamine 16 8.20 Low Low
Neurobehavioral 36 5.00 Very Low Very Low Very Low
cerebral cortex 18 5.00 Very Low Very Low Very Low
corticosteroid 12 5.00 Very Low Very Low Very Low
palliative 9 5.00 Very Low Very Low Very Low
Inflammation 9 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Mucopolysaccharidosis Ii 39 99.80 Very High Very High Very High
Disease 157 99.20 Very High Very High Very High
Airway Obstruction 13 96.76 Very High Very High Very High
Myocardial Infarction 9 95.88 Very High Very High Very High
Apoptosis 36 92.60 High High
Death 34 92.04 High High
Lysosomal Storage Diseases 33 85.24 High High
Targeted Disruption 8 79.76 Quite High
Neurodegenerative Disease 4 74.04 Quite High
Retina Disease 13 70.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Idursulfase is a purified form of iduronate-2-sulfatase produced in a human cell line via recombinant DNA technology.
Gene_expression (produced) of iduronate-2-sulfatase
1) Confidence 0.71 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721351 Disease Relevance 0.13 Pain Relevance 0
The group C treatment showed that IDS can also be partially detected in MPSII mice of 7 months of age, even when these mice were treated once every 7 days (Fig. 1C).
Gene_expression (detected) of IDS
2) Confidence 0.68 Published 2010 Journal Human Molecular Genetics Section Body Doc Link PMC2989894 Disease Relevance 0 Pain Relevance 0
Immunofluorescence analyses were carried out for the detection of NeuN, GFAP and CD68 (36,37) and for the co-localization signal of Lamp2-hIDS.
Gene_expression (detection) of IDS
3) Confidence 0.65 Published 2010 Journal Human Molecular Genetics Section Body Doc Link PMC2989894 Disease Relevance 0.09 Pain Relevance 0
Figure 1.IDS activities following ERT, measured in brain homogenates of untreated wild-type (wt; n = 5) and MPSII (Idsy/-; n = 5) mice and treated MPSII mice sacrificed 4 h after the final IDS treatments (as indicated).
Gene_expression (activities) of IDS in brain
4) Confidence 0.59 Published 2010 Journal Human Molecular Genetics Section Body Doc Link PMC2989894 Disease Relevance 0 Pain Relevance 0
The IDS assay was performed as described previously (35): briefly, 50 µg total protein extract was incubated with 20 µl of the fluorogenic substrate, 4-methylumbelliferyl-?
Gene_expression (assay) of IDS
5) Confidence 0.59 Published 2010 Journal Human Molecular Genetics Section Body Doc Link PMC2989894 Disease Relevance 0 Pain Relevance 0
These plasma IDS activities returned to the levels measured in the untreated MPSII mice 72 h after the last injections of each treatment protocol (data not shown).
Gene_expression (activities) of IDS in plasma
6) Confidence 0.59 Published 2010 Journal Human Molecular Genetics Section Body Doc Link PMC2989894 Disease Relevance 0 Pain Relevance 0
Thus, to evaluate the residual IDS activity, a group of adult MPSII mice (aged 2 months; n = 4) were treated with 1.2 mg/kg IDS once every 7 days (group E) for 1 month, and 4 days after the final IDS injection, they were sacrificed.
Gene_expression (injection) of IDS
7) Confidence 0.59 Published 2010 Journal Human Molecular Genetics Section Body Doc Link PMC2989894 Disease Relevance 0 Pain Relevance 0
IDS activity and GAG clearance in the brains and tissues of treated and control mice sacrificed 4 days after the final IDS infusion
Gene_expression (infusion) of IDS in brains
8) Confidence 0.59 Published 2010 Journal Human Molecular Genetics Section Body Doc Link PMC2989894 Disease Relevance 0 Pain Relevance 0
No IDS activity can be detected in any of its tissues, and the affected mice show progressive accumulation of GAGs in all of their organs, along with neuropathological defects.
Gene_expression (detected) of IDS
9) Confidence 0.53 Published 2010 Journal Human Molecular Genetics Section Body Doc Link PMC2989894 Disease Relevance 0.85 Pain Relevance 0.15
Surprisingly, the same IDS activities were detected in the group B mice, which received 1.2 mg/kg doses at longer time intervals, i.e. treatment every 4 and 7 days (Fig. 1B).
Gene_expression (detected) of IDS
10) Confidence 0.53 Published 2010 Journal Human Molecular Genetics Section Body Doc Link PMC2989894 Disease Relevance 0 Pain Relevance 0
These results suggest that significant overexpression of IDS in peripheral (liver) tissue may allow penetration of IDS at low levels past the blood brain barrier.
Gene_expression (overexpression) of IDS in blood
11) Confidence 0.48 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721351 Disease Relevance 0.06 Pain Relevance 0.05
Friso and colleagues (Friso et al 2005) evaluated an alternate delivery system by intraperitoneally implanting alginate microcapsules containing C2C12 murine myoblasts overexpressing IDS into ids y/- mice.
Gene_expression (overexpressing) of IDS in myoblasts
12) Confidence 0.48 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721351 Disease Relevance 0.08 Pain Relevance 0.04
Gene therapy offers significant potential for the treatment/cure of genetic diseases such as MPS II and several attempts to express iduronate sulfatase through gene therapy approaches have been investigated (Stroncek et al 1999; Hong et al 2003).
Gene_expression (express) of iduronate sulfatase associated with disease
13) Confidence 0.48 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721351 Disease Relevance 0.39 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox